<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Cardiol Cardiovasc Risk Prev</journal-id><journal-id journal-id-type="iso-abbrev">Int J Cardiol Cardiovasc Risk Prev</journal-id><journal-title-group><journal-title>International Journal of Cardiology. Cardiovascular Risk and Prevention</journal-title></journal-title-group><issn pub-type="epub">2772-4875</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38111519</article-id><article-id pub-id-type="pmc">PMC10726421</article-id><article-id pub-id-type="pii">S2772-4875(23)00054-5</article-id><article-id pub-id-type="doi">10.1016/j.ijcrp.2023.200221</article-id><article-id pub-id-type="publisher-id">200221</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>The risk patients with AGHD have of developing CVD<sup><xref ref-type="fn" rid="d35e10">&#x02606;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Javed</surname><given-names>Eisha</given-names></name><email>eishajaved01@gmail.com</email></contrib><contrib contrib-type="author" id="au2"><name><surname>Zehra</surname><given-names>Maha</given-names></name><email>mahazehra562@gmail.com</email></contrib><contrib contrib-type="author" id="au3"><name><surname>Elahi</surname><given-names>Naz</given-names></name><email>nazelahi73@gmail.com</email><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1">Department of Medicine, Dow Medical College, Karachi, Pakistan</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. <email>nazelahi73@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>13</day><month>10</month><year>2023</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>12</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>10</month><year>2023</year></pub-date><volume>19</volume><elocation-id>200221</elocation-id><history><date date-type="received"><day>12</day><month>6</month><year>2023</year></date><date date-type="rev-recd"><day>22</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>12</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 The Authors. Published by Elsevier B.V.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Pituitary disorder</kwd><kwd>Growth hormone</kwd><kwd>Cardiovascular disease</kwd><kwd>Endocrinology</kwd></kwd-group></article-meta><notes><p id="misc0010">Handling editor: D Levy</p></notes></front><body><sec id="sec1"><title>Funding information</title><p id="p0010">None to declare.</p></sec><sec id="sec2"><title>Competing interest statement</title><p id="p0015">None to declare for any author.</p><p id="p0020">Adult Growth Hormone Deficiency (AGHD) is an endocrine disorder that is characterized by a decreased level of secretion of Growth Hormone, from the anterior pituitary gland in the diencephalon of the brain. Approximately 6000 new cases of AGHD are diagnosed annually in the United States, less than 20&#x000a0;% of which represent early diagnosis in childhood [<xref rid="bib1" ref-type="bibr">1</xref>]. This disease can be caused by congenital pituitary developmental defects, problems in hypothalamic GHRH production or release, and genetic mutation. It can also be caused by injuries to the Central Nervous System, which can be caused by tumors, trauma, radiation, and inflammatory diseases [<xref rid="bib2" ref-type="bibr">2</xref>]. The patients suffering from AGHD have a poor quality of life, reduced life expectancy, and an increased risk of developing Cardiovascular (CV) disorders [<xref rid="bib3" ref-type="bibr">3</xref>].</p><p id="p0025">It has been proven that growth hormone plays a significant role in regulating the development of the heart, and its vascular endothelium, which helps the heart maintain its normal structure and function [<xref rid="bib4" ref-type="bibr">4</xref>]. Deficiency of this hormone may result in CV developmental abnormalities, including decreased ventricular mass, reduced cardiac output, unfavorable alternations in lipid profile, and diminished diastolic and systolic function [<xref rid="bib5" ref-type="bibr">5</xref>].</p><p id="p0030">According to a recent study conducted by Kim et al., the CV mortality rate in adults diagnosed with AGHD was approximately twice that of those not suffering from the disease, proving its effects on CV health [<xref rid="bib6" ref-type="bibr">6</xref>]. This can be due to the fact that the disease is characterized by increased oxidative stress, elevated fibrinogen, elevated Plasminogen Activator Inhibitor-1 activity, and higher than normal levels of low-density proteins (LDL) than high-density proteins (HDL) [<xref rid="bib7" ref-type="bibr">7</xref>]. All of these factors lead to a higher risk of developing atherosclerosis and hypertension, both of which increase the chances of developing CV disease. In addition to this, a study conducted by Maison et al. which analyzed the life expectancy of patients with hypopituitarism, has also suggested that patients afflicted with AGHD have a fifty percent higher chance of vascular mortality [<xref rid="bib8" ref-type="bibr">8</xref>].</p><p id="p0035">In recent years, Recombinant human growth hormone replacement therapy (RGHRT) has been used to treat patients of AGHD, in order to improve their quality of life. In this treatment, synthetic growth hormone injections are administered subcutaneously and are generally considered safe, and effective. A research investigation conducted to evaluate the efficacy of RGHRT has suggested that the treatment with GH was associated with a significant improvement in cardiac structure and function [<xref rid="bib8" ref-type="bibr">8</xref>]. Possible reasons for this can be a decrease in the atherogenic ratio, improving systolic function, and standardizing cardiac mass [<xref rid="bib9" ref-type="bibr">9</xref>]. Furthermore, a long-term 15-year prospective research verified the beneficial effect of this treatment on lipid profile, which demonstrates one of the many benefits of RGHRT therapy in AGHD patients [<xref rid="bib10" ref-type="bibr">10</xref>]. However, these injections have undeniable side effects, including edema, arthralgia, and paresthesia, which raise questions regarding safety [<xref rid="bib10" ref-type="bibr">10</xref>]. Therefore, researchers need to take steps to develop newer treatments, with less dangerous side effects, in order to help AGHD patients.</p><p id="p0040">Furthermore, many cases of AGHD are not diagnosed in childhood, which highlights the importance of raising awareness about this condition, as it not only impacts the patients&#x02019; memory and mood but also has detrimental effects on their CV function. Doctors should encourage patients to make changes to their lifestyle to boost Human Growth hormone naturally, such as exercising and taking arginine supplements [<xref rid="bib11" ref-type="bibr">11</xref>]. These methods could help decrease the CV risk in these patients, reducing the risk of mortality.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Shimon</surname><given-names>I.</given-names></name><name><surname>Badiu</surname><given-names>C.</given-names></name><name><surname>Bossowski</surname><given-names>A.</given-names></name><name><surname>Doknic</surname><given-names>M.</given-names></name><name><surname>Dzivite-Krisane</surname><given-names>I.</given-names></name><name><surname>H&#x000e1;na</surname><given-names>V.</given-names></name><name><surname>Kollerova</surname><given-names>J.</given-names></name><name><surname>Natchev</surname><given-names>E.</given-names></name><name><surname>Pfeifer</surname><given-names>M.</given-names></name><name><surname>Sz&#x00169;cs</surname><given-names>N.</given-names></name><name><surname>Hey-Hadavi</surname><given-names>J.</given-names></name><name><surname>Gomez</surname><given-names>R.</given-names></name></person-group><article-title>Adult growth hormone deficiency in CEE region: heterogeneity of the patient pathway</article-title><source>Growth Hormone IGF Res.</source><volume>46&#x02013;47</volume><year>2019 Jun-Aug</year><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ghir.2019.06.001</pub-id><comment>Epub 2019 Jun 7. PMID: 31234055</comment></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Di Iorgi</surname><given-names>N.</given-names></name><name><surname>Morana</surname><given-names>G.</given-names></name><name><surname>Allegri</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>Classical and non-classical causes of GH deficiency in the paediatric age</article-title><source>Best Pract. Res. Clin. Endocrinol. Metabol.</source><volume>30</volume><issue>6</issue><year>2016</year><fpage>705</fpage><lpage>736</lpage></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Gazzaruso</surname><given-names>C.</given-names></name><name><surname>Gola</surname><given-names>M.</given-names></name><name><surname>Karamouzis</surname><given-names>I.</given-names></name><name><surname>Giubbini</surname><given-names>R.</given-names></name><name><surname>Giustina</surname><given-names>A.</given-names></name></person-group><article-title>Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update</article-title><source>J. Clin. Endocrinol. Metab.</source><volume>99</volume><issue>1</issue><year>2014</year><fpage>18</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">24217903</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Caicedo</surname><given-names>D.</given-names></name><name><surname>Devesa</surname><given-names>P.</given-names></name><name><surname>Alvarez</surname><given-names>C.V.</given-names></name><name><surname>Devesa</surname><given-names>J.</given-names></name></person-group><article-title>Why should growth hormone (GH) Be considered a promising therapeutic agent for arteriogenesis? Insights from the GHAS trial</article-title><source>Cells</source><volume>9</volume><issue>4</issue><year>2020 Mar 27</year><fpage>807</fpage><pub-id pub-id-type="doi">10.3390/cells9040807</pub-id><comment>PMID: 32230747; PMCID: PMC7226428</comment><pub-id pub-id-type="pmid">32230747</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Isgaard</surname><given-names>J.</given-names></name><name><surname>Cittadini</surname><given-names>A.</given-names></name></person-group><article-title>Growth hormone and the heart in growth hormone deficiency-what have we learned so far?</article-title><source>Endocrine</source><volume>55</volume><issue>2</issue><year>2017</year><fpage>331</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">27981513</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Chae</surname><given-names>H.W.</given-names></name><name><surname>Chin</surname><given-names>S.O.</given-names></name><etal/></person-group><article-title>Diagnosis and treatment of growth hormone deficiency: a position statement from Korean endocrine society and Korean society of pediatric endocrinology</article-title><source>Endocrinol Metab (Seoul)</source><volume>35</volume><issue>2</issue><year>2020</year><fpage>272</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">32615711</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Gazzaruso</surname><given-names>C.</given-names></name><name><surname>Gola</surname><given-names>M.</given-names></name><name><surname>Karamouzis</surname><given-names>I.</given-names></name><name><surname>Giubbini</surname><given-names>R.</given-names></name><name><surname>Giustina</surname><given-names>A.</given-names></name></person-group><article-title>Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update</article-title><source>J. Clin. Endocrinol. Metab.</source><volume>99</volume><issue>1</issue><year>2014</year><fpage>18</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-2394</pub-id><pub-id pub-id-type="pmid">24217903</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Isgaard</surname><given-names>J.</given-names></name></person-group><article-title>Cardiovascular disease and risk factors: the role of growth hormone</article-title><source>Horm. Res.</source><volume>62</volume><issue>Suppl 4</issue><year>2004</year><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">15591764</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Metwalley</surname><given-names>K.A.</given-names></name><name><surname>Farghaly</surname><given-names>H.S.</given-names></name><name><surname>Abd El-Hafeez</surname><given-names>H.A.</given-names></name></person-group><article-title>Evaluation of left ventricular mass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: a single-center prospective case-control study</article-title><source>Indian J Endocrinol Metab</source><volume>17</volume><issue>5</issue><year>2013</year><fpage>876</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.4103/2230-8210.117234</pub-id><pub-id pub-id-type="pmid">24083170</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>D&#x000ed;ez</surname><given-names>J.J.</given-names></name><name><surname>Sangiao-Alvarellos</surname><given-names>S.</given-names></name><name><surname>Cordido</surname><given-names>F.</given-names></name></person-group><article-title>Treatment with growth hormone for adults with growth hormone deficiency syndrome: benefits and risks</article-title><source>Int. J. Mol. Sci.</source><volume>19</volume><issue>3</issue><year>2018</year><fpage>893</fpage><comment>Published 2018 Mar 17</comment><pub-id pub-id-type="pmid">29562611</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Kanaley</surname><given-names>J.A.</given-names></name></person-group><article-title>Growth hormone, arginine and exercise</article-title><source>Curr. Opin. Clin. Nutr. Metab. Care</source><volume>11</volume><issue>1</issue><year>2008</year><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1097/MCO.0b013e3282f2b0ad</pub-id><pub-id pub-id-type="pmid">18090659</pub-id>
</element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgements</title><p id="p0045">None to declare.</p></ack><fn-group><fn id="d35e10"><label>&#x02606;</label><p id="ntpara0010">All the authors verify that they had access to the data and had a role in writing the manuscript.</p></fn></fn-group></back></article>
